You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
SBC: Flow Pharma, Inc. Topic: CBD18A002
Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: Senvol LLC Topic: DLA18A001
The Department of Defense (DoD) has a demand for out-of-production parts to maintain mission readiness of various weapons platforms. Additive manufacturing (AM) is an exciting and promising manufacturing technique that can make out-of-production parts and holds the potential to solve supply chain issues, such as high costs (i.e. for low-volume parts) and sole sourcing risks. The ability of AM to s ...STTR Phase I 2018 Department of DefenseDefense Logistics Agency
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense